Topic Review
Modelling the Human Placental Interface In Vitro
Acting as the primary link between mother and fetus, the placenta is involved in regulating nutrient, oxygen, and waste exchange; thus, healthy placental development is crucial for a successful pregnancy. In line with the increasing demands of the fetus, the placenta evolves throughout pregnancy, making it a particularly difficult organ to study. Research into placental development and dysfunction poses a unique scientific challenge due to ethical constraints and the differences in morphology and function that exist between species. An alternative is to create an in vitro model of the human placenta. Advancements in the differentiation of human induced pluripotent stem cells (hiPSCs), microfluidics, and bioprinting have each contributed to the development of new models, which can be designed to closely match physiological in vivo conditions. By including relevant placental cell types and control over the microenvironment, these in vitro models can reveal clues to the pathogenesis of placental dysfunction and facilitate drug testing across the maternal-fetal interface. 
  • 782
  • 02 Dec 2021
Topic Review
GnRH
GnRH receptors are expressed in other reproductive organs, such as the ovary and in tumors originating from the ovary. In ovarian cancer, GnRH is involved in the regulation of proliferation and metastasis. The effects on ovarian tumors can be indirect or direct. GnRH acts indirectly via the HPG axis and directly via GnRH receptors on the surface of ovarian cancer cells.
  • 756
  • 07 Apr 2021
Topic Review
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer (BC). 
  • 748
  • 22 Apr 2022
Topic Review
Neoadjuvant Chemotherapy in Breast Cancer
Neoadjuvant chemotherapy is increasingly being employed in the management of breast cancer patients. To ensure that health care needs are adequately addressed, clinicians must consider that women with breast cancer have a high risk of developing “unmet needs” during treatment, and often require a clinical intervention or additional care resources to limit possible complications and psychological issues that can occur during neoadjuvant treatment.
  • 744
  • 27 May 2021
Topic Review
Whole Ovary Cryopreservation and Transplantation
The aim of this systematic review is to shed light on the challenges of whole ovary cryopreservation and transplantation and to summarize the solutions that have been proposed so far in animal experiments and humans in order to stimulate further research in the field.
  • 740
  • 16 Oct 2020
Topic Review
Premature Ovarian Insufficiency and Infertility
Reproductive aging is on the rise globally and inseparable from the entire aging process. An extreme form of reproductive aging is premature ovarian insufficiency (POI), which to date has mostly been of idiopathic etiology, thus hampering further clinical applications and associated with enormous socioeconomic and personal costs. In the field of reproduction, timely diagnosis with a clear understanding of the various comorbidities that can arise from estrogen deficiency and the important functional role of inflammation-induced ovarian deterioration are research hotspots for appropriate counseling and preventing this prematurely ovarian aging disease. It is evident that more research is required to allow pre-emptive identification of the at-risk population and to identify mechanisms that, if addressed promptly, can prolong ovarian function and fertility.
  • 723
  • 30 Dec 2022
Topic Review
Bacterial Vaginosis
Bacterial vaginosis (BV) has been reported in one-third of women worldwide at different life stages, due to the complex balance in the ecology of the vaginal microbiota. It is a common cause of abnormal vaginal discharge and is associated with other health issues. Since the first description of anaerobic microbes associated with BV like Gardnerella vaginalis in the 1950s, researchers have stepped up the game by incorporating advanced molecular tools to monitor and evaluate the extent of dysbiosis within the vaginal microbiome, particularly on how specific microbial population changes compared to a healthy state. Moreover, treatment failure and BV recurrence rate remain high despite the standard antibiotic treatment. Consequently, researchers have been probing into alternative or adjunct treatments, including probiotics or even vaginal microbiota transplants, to ensure successful treatment outcomes and reduce the colonization by pathogenic microbes of the female reproductive tract. 
  • 713
  • 29 Jul 2021
Topic Review
ADHOGD
Adolescent dietary habit-induced obstetric and gynecologic disease (ADHOGD) is dieting and breakfast skipping during adolescence and adulthood, impair development and maturation of the reproductive function (1), which induces latent progression of obstetrics and gynecologic disorders (2). Although recovery is achieved after correcting adverse eating habits (3), the reproductive function declines (4), and this leads to the latter onset of obstetrics and gynecologic diseases (5).
  • 710
  • 29 Oct 2020
Topic Review
The Gender Gap in Infertility
The gender impact assessment (GIA) can be defined as an ex ante or ex post evaluation, analysis, or assessment of law, policy, or programme that helps to identify the likelihood of a decision having negative consequences for equality between women and men. GIA is aimed at improving the design and planning policy to prevent a negative effect on gender equality and improve gender equality through gender-oriented strategies.
  • 710
  • 22 Jun 2021
Topic Review
Ovarian Cancer Biomarkers
Ovarian cancer is the eighth-most common cause of death among women worldwide. In the absence of distinctive symptoms in the early stages, the majority of women are diagnosed in advanced stages of the disease. Surgical debulking and systemic adjuvant chemotherapy remain the mainstays of treatment, with the development of chemoresistance in up to 75% of patients with subsequent poor treatment response and reduced survival. Therefore, there is a critical need to revisit existing, and identify potential biomarkers that could lead to the development of novel and more effective predictors for ovarian cancer diagnosis and prognosis. The capacity of these biomarkers to predict the existence, stages, and associated therapeutic efficacy of ovarian cancer would enable improvements in the early diagnosis and survival of ovarian cancer patients. 
  • 705
  • 15 Apr 2021
  • Page
  • of
  • 33